Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Sarcoma 4Gliosarcoma 4Glioblastoma 4Brain Neoplasms 3Ovarian Neoplasms 2Oligodendroglioma 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Soft Tissue Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Melanoma 1Lymphangioleiomyomatosis 1Liposarcoma 1Leiomyosarcoma 1Hemangiosarcoma 1Glioma 1

Interventions

Temozolomide 45Radiotherapy 20Filgrastim 17Carmustine 15Carboplatin 15Irinotecan 13Bevacizumab 13Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 11Peripheral Blood Stem Cell Transplantation 9Erlotinib Hydrochloride 9sargramostim 8O(6)-benzylguanine 8Radiation 7Topotecan 6Thiotepa 6Radiotherapy, Intensity-Modulated 6Procarbazine 6Etoposide 6Drug Therapy 6Cyclophosphamide 6Chemotherapy, Adjuvant 6aldesleukin 5Vorinostat 5Sirolimus 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Busulfan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5temsirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × Disulfides × Sarcoma × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡